Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Cartesian Therapeutics (RNAC) Change in Taxes (2021 - 2022)

Cartesian Therapeutics (RNAC) has disclosed Change in Taxes for 2 consecutive years, with -$321000.0 as the latest value for Q3 2022.

For Q3 2022, Change in Taxes fell 102.03% year-over-year to -$321000.0; the TTM value through Jun 2023 reached -$321000.0, down 200.0%, while the annual FY2022 figure was -$601000.0, 200.0% down from the prior year.
Change in Taxes hit -$321000.0 in Q3 2022 for Cartesian Therapeutics, down from $1000.0 in the prior quarter.
Across five years, Change in Taxes topped out at $15.8 million in Q3 2021 and bottomed at -$15.2 million in Q4 2021.